Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25434814 | 0.86 | OPRK1 (0.40) | IRAK4KDM4EALDH1A1OPRK1 | |
| SCHEMBL30720464 | 0.84 | OPRK1 (0.39) | IRAK4MEN1KMT2ASMN1; SMN2OPRK1 | |
| SCHEMBL26053358 | 0.83 | OPRK1 (0.38) | IRAK4KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL25431879 | 0.83 | CA12 (0.38) | IRAK4KDM4EALDH1A1SMN1; SMN2OPRK1 | |
| SCHEMBL26914790 | 0.82 | SMN1; SMN2 (0.35) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL26914782 | 0.82 | SMN1; SMN2 (0.35) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL25433261 | 0.81 | BAZ2B (0.39) | IRAK4ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL27186169 | 0.81 | OPRK1 (0.42) | IRAK4ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL27186173 | 0.81 | ALDH1A1 (0.45) | IRAK4KDM4EALDH1A1GLAHSD17B10 | |
| SCHEMBL25710619 | 0.81 | ALDH1A1 (0.39) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-20230265090-A1 | QUINAZOLINE COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265090-A1 | QUINAZOLINE COMPOUND | ABCG2, CYP3A7, ABL1 | IRAK4 3234/4885KDM4E 2942/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.